Skip to main content
SpringerLink
Log in

Bisphosphonates in the Treatment of Metastatic Breast Cancer

  • Published:
Journal of Mammary Gland Biology and Neoplasia Aims and scope Submit manuscript

Abstract

The skeleton is the most common site of metastatic disease in breast cancer and the most common site of first distant relapse. Bone metastases in breast cancer are the source of considerable morbidity, including severe pain, pathological fractures, need for radiotherapy or surgery, and hypercalcemia. Bisphosphonates are potent inhibitors of osteoclast-mediated bone resorption, and it is well known that breast cancer cells in bone can stimulate osteoclast formation and activity leading to the release of growth factors and cytokines, which will further stimulate cancer cell growth and their secretion of osteolytic factors. We are thus typically dealing with a vicious cycle, as the bone resorption-induced release of growth factors from the bone matrix will stimulate breast cancer cell growth (probably mainly by IGFs) and the production of the osteolytic factor PTHrP (probably mainly by TGF-β but also by extracellular calcium). Clodronate, but not the aminobisphosphonates, can be metabolized to an ATP analog that is toxic for osteoclasts. Nitrogen-containing bisphosphonates, such as pamidronate, ibandronate, and zoledronate, interfere with the mevalonate pathway that is crucial to maintain cell membrane integrity. The net result, regardless of the mechanism, is osteoclast apoptosis, notably through the induction of caspase-3. Bisphosphonates are now the standard treatment for cancer hypercalcemia. Repeated bisphosphonate infusions also exert clinically relevant analgesic effects in at least one half of the patients with metastatic bone pain. Most importantly, prolonged administration of bisphosphonates (for at least 1 year) reduces the frequency of morbid skeletal events by 30–40% in breast cancer metastatic to bone and in up to 50% in patients with multiple myeloma. Newer bisphosphonates, such as ibandronate and zoledronate, will simplify the current therapeutic schemes and improve the cost-effectiveness ratio, and they have the potential to improve the therapeutic efficacy, at least in patients with aggressive osteolytic disease or in the adjuvant setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. J. J. Body (1999). Bone metastases. In J. Klastersky, S. C. Schimpff, and H. J. Senn (eds.), Handbook of Supportive Care in Cancer, 2nd edn., Marcel Dekker, New York, pp. 453-481.

    Google Scholar 

  2. R. E. Coleman and R. D. Rubens (1987). The clinical course of bone metastases from breast cancer. Br. J. Cancer 55:61-66.

    Google Scholar 

  3. J. J. Body, D. Lossignol, and A. Ronson (1997). The concept of rehabilitation of cancer patients. Curr. Opin. Oncol. 9:332-340.

    Google Scholar 

  4. M. M. Sherry, F.A. Greco, D.H. Johnson, and J.D. Hainsworth (1986). Metastatic breast cancer confined to the skeletal system. An indolent disease. Am. J. Med. 81:381-386.

    Google Scholar 

  5. R. E. Coleman, P. Smith, and R. D. Rubens (1998). Clinical course and prognostic factors following recurrence from breast cancer. Br. J. Cancer 17:336-340.

    Google Scholar 

  6. S. M. Domchek, J. Younger, D. M. Finkelstein, and M. Seiden (2000). Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 89:363-368.

    Google Scholar 

  7. J. J. Body (2000). Tumor Bone Diseases and Osteoporosis in Cancer Patients, Marcel Dekker, New York.

    Google Scholar 

  8. J. J. Body, J. C. Dumon, E. Gineyts, and P. D. Delmas (1997). Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br. J. Cancer 75:408-412.

    Google Scholar 

  9. T. Taube, I. Elomaa, C. Blomqvist, M. N. C. Beneton, and J. A. Kanis (1994). Histomorphometric evidence for osteoclastmediated bone resorption in metastatic breast cancer. Bone 15:161-166.

    Google Scholar 

  10. B. Siwek, M. Lacroix, C. de Pollak, P. Marie, and J. J. Body (1997). Secretory products of breast cancer cells affect human osteoblastic cells: Partial characterization of active factors. J. Bone Miner. Res. 12:552-560.

    Google Scholar 

  11. M. Lacroix, P. J. Marie, and J. J. Body (2000). Protein production by osteoblasts: Modulation by breast cancer cell-derived factors. Breast Cancer Res. Treat. 61:59-67.

    Google Scholar 

  12. O. Fromigué, N. Kheddoumi, A. Lomri, P. J. Marie, and J. J. Body (2001). Breast cancer cells release factors that induce apoptosis in human bone marrow stromal cells. J. Bone Miner. Res. 16:1600-1610.

    Google Scholar 

  13. G. R. Mundy (1997). Mechanisms of bone metastasis. Cancer 80:1546-1556.

    Google Scholar 

  14. J. L. Sanders, N. Chattopadhyay, O. Kifor, T. Yamaguchi, R. R. Butters, and E. M. Brown (2000). Extracellular calciumsensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 141:4357-4364.

    Google Scholar 

  15. T. A. Guise (2001). Cancer and bone. Bone 28(Suppl.):S68.

    Google Scholar 

  16. Z. Zimolo, G. Wesolowski, and G. A. Rodan (1995). Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J. Clin. Invest. 96:2277-2283.

    Google Scholar 

  17. J.C. Frith, J. Mönkkönen, G. M. Blackburn, R.G.G. Russel, and M. J. Rogers (1997). Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 50'(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. 12:1358-1367.

    Google Scholar 

  18. S. P. Luckman, D. E. Hughes, F. P. Coxon, R. G. G. Russell, and M. J. Rogers (1998). Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J. Bone Miner. Res. 13:581-589.

    Google Scholar 

  19. E. Van Beek, C. Lowik, G. van der Pluijm, and S. Papapoulos (1999). The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism ogf action of nitrogencontaining bisphosphonates. J. Bone Miner. Res. 14:722-729.

    Google Scholar 

  20. J. J. Body (2000). Bisphosphonates as chemotherapeutic agents. Curr. Opin. Oncol., Endo. Metab. Invest. Drugs 2:155-161.

    Google Scholar 

  21. O. Fromigué, L. Lagneaux, and J. J. Body (2000). Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15:2211-2221.

    Google Scholar 

  22. S. Derenne, M. Amiot, S. Barille, M. Collette, N. Robillard, P. Berthaud, J. L. Harousseau, and R. Bataille (1999). Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res. 14:2048-2056.

    Google Scholar 

  23. J. J. Body (2000). Current and future directions in medical therapy: Hypercalcemia. Cancer 88:3054-3058.

    Google Scholar 

  24. O. P. Purohit, C. R. Radstone, C. Anthony, J. A. Kanis, and R. E. Coleman (1995). A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br. J. Cancer 72:1289-1293.

    Google Scholar 

  25. J. J. Body and J. C. Dumon (1994). Treatment of tumor-induced hypercalcaemia with the bisphosphonate pamidronate: Doseresponse relationship and influence of the tumour type. Ann. Oncol. 5:359-363.

    Google Scholar 

  26. J. Walls, W. A. Ratcliffe, A. Howell, and N. J. Bundred (1994). Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: The role of parathyroid hormone-related protein. Br. J. Cancer 70: 169-172.

    Google Scholar 

  27. J. J. Body, I. Louviaux, and J. C. Dumon (2000). Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. J. Support. Care Cancer 8:398-404.

    Google Scholar 

  28. S. H. Ralston, D. Thiébaud, Z. Herrmann, E. U. Steinhauer, B. Thurlimann, J. Walls, M. R. Lichinitser, R. Rizzoll, H. Hagberg, H. J. Huss, M. Tubiana-Hulin, and J. J. Body (1997). Dose-response study of ibandronate in treatment of cancer-associated hypercalcaemia. Br. J. Cancer 75:295-300.

    Google Scholar 

  29. J. J. Body, A. Lortholary, G. Romieu, A. M. Vigneron, and J. Ford (1999). A dose-finding study of zoledronate in hypercalcemic cancer patients. J. Bone Miner. Res. 14:1557-1561.

    Google Scholar 

  30. P. Major, A. Lortholary, J. Hon, E. Abdi, G. Mills, H. D. Menssen, F. Yunus, R. Bell, J. J. Body, E. Quebe-Fehling, and J. Seaman (2001). Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19:558-567.

    Google Scholar 

  31. A. G. Robertson, N. S. Reed, and S. H. Ralston (1995). Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study. J. Clin. Oncol. 13:2427-2430.

    Google Scholar 

  32. J. J. Body, R. Bartl, P. Burckhardt, P. D. Delmas, I. J. Diel, H. Fleisch, J. A. Kanis, R. A. Kyle, G. R. Mundy, A. H. G. Paterson, and R. D. Rubens, for the International Bone and Cancer Study Group (1998). Current use of bisphosphonates in oncology. J. Clin. Oncol. 16:3890-3899.

    Google Scholar 

  33. J. J. Body, R. E. Coleman, and M. Piccart (1996). Use of bisphosphonates in cancer patients. Cancer Treat. Rev. 22:265-287.

    Google Scholar 

  34. D. S. Ernst, P. Brasher, N. Hagen, A. H. Paterson, R. N. MacDonald, and E. Bruera (1997). A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J. Pain Symptom Manage. 13:319-326.

    Google Scholar 

  35. J. J. Body (1999). Bisphosphonates for metastatic bone pain. J. Support. Care Cancer 7:1-3.

    Google Scholar 

  36. J. J. F. Vinholes, O. P. Purohit, M. E. Abbey, R. Eastell, and R. E. Coleman (1997). Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann. Oncol. 8:1243-1250.

    Google Scholar 

  37. J. C. Dumon, I. Mancini, and J. J. Body (2001). Clinical and biochemical effects of a short-term ibandronate treatment in cancer patients with opioid-resistant metastatic bone pain. Bone 28(Suppl.):S139.

    Google Scholar 

  38. B. E. Hillner, J. N. Ingle, J. R. Berenson, N. A. Janjan, K. S. Albain, A. Lipton, G. Yee, J. S. Biermann, R. T. Chlebowski, and D. G. Pfister (2000). American Society of Clinical Oncology guidelines on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J. Clin. Oncol. 18:1378-1391.

    Google Scholar 

  39. A. H. G. Paterson, T. J. Powles, J. A. Kanis, E. McCloskey, J. Hanson, and S. Ashley (1993). Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. 11:59-65.

    Google Scholar 

  40. P. F. Conte, J. Latreille, L. Mauriac, F. Calabresi, R. Santos, D. Campos, J. Bonneterre, G. Francini, and J. M. Ford (1996). Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomised controlled trial. J. Clin. Oncol. 14:2552-2559.

    Google Scholar 

  41. R. L. Theriault, A. Lipton, G. N. Hortobagyi, R. Leff, S. Gluck, J. F. Stewart, S. Costello, I. Kennedy, J. Simeone, J. J. Seaman, R. D. Knight, K. Mellars, M. Heffernan, and D. J. Reitsma (1999). Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. J. Clin. Oncol. bf 17:846-854.

    Google Scholar 

  42. G. N. Hortobagyi, R. L. Theriault, A. Lipton, L. Porter, D. Blayney, C. Sinoff, H. Wheeler, J. F. Simeone, J. J. Seaman, R. D. Knight, M. Heffernan, K. Mellars, and D. J. Reitsma (1998). Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:2038-2044.

    Google Scholar 

  43. A. Lipton, R. L. Theriault, G. N. Hortobagyi, J. Simeone, R. D. Knight, K. Mellars, D. J. Reitsma, M. Heffernan, and J. J. Seaman (2000). Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082-1090.

    Google Scholar 

  44. R. J. Cook and P. Major (2001). Methodology for treatment evaluation in patients with cancer metastases to bone. J. Natl. Cancer Inst. 93:488-489.

    Google Scholar 

  45. B. E. Hillner, J. C. Weeks, C. E. Desch, and T. J. Smith (2000). Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis. J. Clin. Oncol. 18:72-79.

    Google Scholar 

  46. T. Mashiba, T. Hirano, C. H. Turner, M. R. Forwood, C. C. Johnston, and D. B. Burr (2000). Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15: 613-620.

    Google Scholar 

  47. A. Lipton, L. Demers, E. Curley, V. Chinchilli, L. Gaydos, G. Hortobagyi, R. Theriault, D. Clemens, L. Costa, J. Seaman, and R. Knight (1998). Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer 34:2021-2026.

    Google Scholar 

  48. J. J. Body, M. R. Lichinitser, I. Diehl, K. Schlosser, E. Pfarr, F. Cavalli, V. Dornoff, V.A. Gorbunova, E. McCloskey, J. Weiss, and J. A. Kanis (1999). Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone. Proc. ASCO 18:575a.

    Google Scholar 

  49. J. R. Berenson, L. S. Rosen, A. Howell, L. Porter, R. E. Coleman, W. Morley, R. Dreicer, S. A. Kuross, A. Lipton, and J. J. Seaman (2001). Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191-1200.

    Google Scholar 

  50. T. Yoneda, A. Sasaki, C. Dunstan, P. J. Williams, F. Bauss, Y. A. De Clerck, and G. R. Mundy (1997). Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest. 99:2509-2517.

    Google Scholar 

  51. I. J. Diel, E. F. Solomayer, S. D. Costa, C. Gollan, R. Goerner, D. Wallwiener, M. Kaufmann, and G. Bastert (1998). Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 339:357-363.

    Google Scholar 

  52. T. Saarto, C. Blomqvist, P. Virkkunen, and I. Elomaa (2001). Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol. 19:10-17.

    Google Scholar 

  53. T. J. Powles, A. H. G. Paterson, A. Nevantaus, S. Legault, M. Pajunen, V. A. Tidy, K. Rosenqvist, I. E. Smith, L. Ottestad, S. Ashley, G. Walsh, E. McCloskey, J.A. Kanis (1998). Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. Proc. ASCO 17:123a.

    Google Scholar 

  54. C. Sotiriou, M. Lacroix, L. Lespagnard, D. Larsimont, M. Paesmans, and J. J. Body (2001). Interleukins-6 and-11 expression in primary breast cancer and subsequent development of bone metatases. Cancer Lett. 169:87-95.

    Google Scholar 

  55. M. A. Richards, S. Braysher, W.M. Gregory, and R. D. Rubens (1993). Advanced breast cancer: Use of resources and cost implications. Br. J. Cancer 67:856-860.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Institut Jules Bordet, Univ. Libre de Bruxelles, 1, rue Héger-Bordet, 1000, Bruxelles, Belgium

    Jean-Jacques Body

Authors
  1. Jean-Jacques Body
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Body, JJ. Bisphosphonates in the Treatment of Metastatic Breast Cancer. J Mammary Gland Biol Neoplasia 6, 477–485 (2001). https://doi.org/10.1023/A:1014795216669

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1014795216669

Search

Navigation